TP53 and pancreatic neoplasm: To determine if similar nuclear size changes are present in pancreatic cancer in vivo, we used 2 independent mouse PDAC models, exocrine-pancreas–specific Cre-activated mutant KRASG12D (KC) and exocrine-pancreas–specific Cre-activated KRASG12D in combination with deletion of Tp53 (KPC) (15, 16) (Supplemental Figure 9, A and B).